New hope for tough prostate cancer: drug cocktail trial launches

NCT ID NCT06059118

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a sequence of three drugs—DFMO, high-dose testosterone, and enzalutamide—in 50 men with metastatic castration-resistant prostate cancer that has progressed on standard therapy. The goal is to see if this combination can lower PSA levels and delay cancer growth. Participants must be asymptomatic and have castrate testosterone levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DFMO (eflornithine), testosterone cypionate, and enzalutamide
What this could lead to: If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. The combination therapy may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.